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Abstract 42 
Loss of bladder control is common after spinal cord injury (SCI) and no causal 43 
therapies are available. Here we investigated if function blocking antibodies against 44 
the nerve fiber growth inhibitory protein Nogo-A applied to rats with severe SCI could 45 
prevent development of neurogenic lower urinary tract dysfunction. Bladder function 46 
of rats with SCI was repeatedly assessed by urodynamic examination in fully awake 47 
animals. Four weeks after SCI, detrusor sphincter dyssynergia had developed in all 48 
untreated or control antibody infused animals. In contrast, 2 weeks of intrathecal anti-49 
Nogo-A-antibody treatment led to a significantly reduced aberrant maximum detrusor 50 
pressure during voiding and a reduction of the abnormal EMG high frequency activity 51 
in the external urethral sphincter. Anatomically, we found higher densities of fibers 52 
originating from the pontine micturition center in the lumbo-sacral grey matter in the 53 
anti-Nogo-A antibody treated animals, as well as a reduced number of inhibitory 54 
interneurons in Lamina X. These results suggest that anti-Nogo-A therapy could have 55 
positive effects on bladder function also clinically. 56 
Significance Statement:  57 
Bladder function is after spinal cord injury completely out of control. Detrusor 58 
sphincter dyssynergia, a potentially live threatening consequence, is greatly feared. 59 
Currently there are only symptomatic treatment options available and first causal 60 
treatment options are urgently needed in humans. In this work we show that function 61 
blocking antibodies against the nerve fiber growth inhibitory protein Nogo-A applied 62 
to rats with severe spinal cord injury could prevent development of neurogenic lower 63 
urinary tract dysfunction, in particular detrusor sphincter dyssynergia. Anti-Nogo-A 64 
therapy enters currently phase II clinical trial in humans and might therefore be soon 65 
the first causal treatment option for neurogenic lower urinary tract dysfunction. 66 
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Introduction 68 
Many neurological diseases that affect descending tract systems, including spinal 69 
cord injury and multiple sclerosis, often lead to severe disturbances of bladder 70 
function. Detrusor sphincter dyssynergia (DSD)(Weld et al., 2000), which is defined 71 
by dys-synergic contractions of the external urethral sphincter during the voiding 72 
phase, is a life-threatening complication as it results in high intravesical pressure with 73 
subsequent urine reflux to the kidneys and, over years, can lead to kidney damage 74 
and eventually renal failure(Groen et al., 2016). Lower urinary tract dysfunction 75 
contributes in a major way to a decreased quality of life in the affected patients and 76 
therefore is one of the highest rehabilitation priorities(Simpson et al., 2012). However, 77 
only a few symptomatic treatment options are currently available including 78 
intermittent self-catheterization four to six times a day, antimuscarinic drugs, and 79 
intradetrusor onabotulinumtoxinA injections(Panicker et al., 2015). These treatments 80 
are at best symptomatic and come at the cost of frequent side effects such as urinary 81 
tract infections, or injuries to the urethra. Causal treatment options for neurogenic 82 
lower urinary tract dysfunctions, in particular DSD, are therefore urgently 83 
needed(Panicker et al., 2015). 84 
The central neuronal circuits controlling lower urinary tract function are not yet fully 85 
understood. Storage and voiding of the urine are achieved by complex interactions 86 
between the somatic and the autonomic nervous system(de Groat et al., 2015). 87 
Although the storage reflex is mainly an intraspinal process(De Groat and Lalley, 88 
1972), the initiation of voiding depends on supraspinal input from a nucleus located in 89 
the pons,  the pontine micturition center (PMC)(Griffiths et al., 1990). The PMC-spinal 90 
projection neurons are excitatory and glutamatergic, with the peculiarity to also 91 
contain the neuropeptide corticotropin-releasing factor (CRF)(Verstegen et al., 2017). 92 
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These neurons send long-projecting axons to the lumbosacral cord and play a 93 
fundamental role in micturition. A lesion to the spinal cord disrupts the neural circuitry 94 
controlling the lower urinary tract function, and the neuro-urological consequences for 95 
the patient depend on the location and the extent of the injury. After a suprasacral 96 
SCI, the voluntary, supraspinal control of voiding is interrupted, leading to an initial 97 
acontractile bladder, causing urinary retention. After weeks to months, depending on 98 
the species, autonomic voiding slowly reappears and culminates in detrusor 99 
overactivity(de Groat et al., 1990), which was hypothesized to be the result of 100 
aberrant intraspinal plasticity with an important contribution by C-fibers(Cheng and de 101 
Groat, 2004). Although bladder contraction reappears over time, voiding is usually 102 
inefficient due to the simultaneous contraction of the external urethral sphincter 103 
together with the detrusor, a phenomenon that is known as detrusor-sphincter 104 
dyssynergia (DSD). DSD arises over time in the majority of patients with an 105 
incomplete or complete spinal cord injury, causing elevated intravesical pressures 106 
that, over time, put the upper urinary tract at risk(Bacsu et al., 2012; Groen et al., 107 
2016).  108 
Bladder function can be determined with high precision by urodynamic 109 
measurements, i.e. by simultaneously assessing the intravesical pressure and 110 
external urethral sphincter electromyography under fully awake conditions(Nosseir et 111 
al., 2007). This clinical protocol has recently been transferred and reproduced in 112 
intact and spinal cord injured rats(Schneider et al., 2015; Foditsch et al., 2018). 113 
The CNS and myelin enriched membrane protein Nogo-A is a potent nerve fiber 114 
growth inhibitory protein, responsible in part for the low level spontaneous neuronal 115 
of regeneration and repair present in the adult mammalian CNS(Schwab, 2010; 116 
Schwab and Strittmatter, 2014). Neutralization by functionally blocking antibodies, 117 
genetic deletion of Nogo-A or blockade of Nogo-A receptors induces substantial 118 
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axonal regeneration, as well as enhanced neuronal plasticity and functional recovery 119 
after SCI or stroke in animal models(Liebscher et al., 2005; Schwab and Strittmatter, 120 
2014; Wahl et al., 2014). It had been noted before that inhibition of Nogo-A in rats 121 
with large but incomplete spinal cord injuries using function blocking antibodies not 122 
only resulted in improved recovery of locomotion, but also led to an earlier restoration 123 
of independent voiding(Liebscher et al., 2005). However, a detailed urodynamic 124 
assessment of bladder function after SCI, assessing the potential of anti-Nogo-A 125 
antibodies as a potential therapy for DSD following spinal cord injury is so far 126 
missing. The present study aims at investigating the effects of anti-Nogo-A antibodies 127 
in the development of neurogenic lower urinary tract dysfunction, in particular DSD, 128 
following a large SCI in adult rats. 129 
130 
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Materials and Methods 131 
Rats: Adult female Lewis rats (LEW/OrlRj (Lewis), of 210 g ± 20 g body weight and 4 132 
mts ± 1mts of age were purchased from Janvier, France. The rats were housed in 133 
groups of three to four per cage, and single housed after catheter implantation, food 134 
(rat chow) and water were provided ad libitum. Rats were maintained on a 12/12 h 135 
light/dark cycle (light on from 6:00 a.m. until 6:00 p.m). All experiments were 136 
approved by the Veterinary Office of the canton of Zürich, Switzerland (License nr. 137 
19/2014) and were in accordance with the approved guidelines and regulations.  138 
Catheter and electrodes implantation: All rats underwent initial preoperative 139 
handling and acclimatization to the urodynamic lab station followed by catheter and 140 
electrode implantation. Procedures were performed as described 141 
previously(Schneider et al., 2015; Foditsch et al., 2018). Briefly, rats were initially 142 
anesthetized in 5% Isoflurane (Piramal Healthcare) in air and maintained by an i.m. 143 
injection of Medetomidine (0.15 mg/kg Domitor, Orion Pharma), Midazolanum (2 144 
mg/kg, Dormicum, Roche) and Fentanyl (5 μg/kg, Fentanyl, Kantonsapotheke 145 
University Hospital Zurich). Bladder catheters were inserted into the bladder dome 146 
and secured with a purse string suture. EMG electrodes were affixed to the fat tissue 147 
beside the external urethral sphincter and a ground electrode was sutured to the 148 
abdominal muscle. Catheter and wires were tunneled subcutaneously to the back of 149 
the neck, exteriorized, and lastly attached to an infusion harness (QC Single, SAI 150 
Infusion Technologies, USA). 151 
Spinal cord injury: Rats were anesthetized as described above. In 41 animals, the 152 
T8 lamina was removed and the dorsal two thirds of the spinal cord were transected 153 
bilaterally microsurgically with iridectomy scissors, resulting in severe but incomplete 154 
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spinal cord injury. In 28 rats, the lower thoracic spinal cord was transected 155 
completely. Seventeen rats were left intact. 156 
Osmotic pump implantation: Fifty-four spinal cord injured rats were implanted with 157 
intrathecal pumps for antibody delivery at the day of spinal cord injury. Following 158 
baseline urodynamic measurements, the rats were divided into four different groups: 159 
incomplete spinal cord injury with control antibody treatment (n= 17), complete spinal 160 
cord injury with control antibody treatment (n= 10), incomplete spinal cord injury with 161 
anti-Nogo-A antibody treatment (n= 16), complete spinal cord injury with anti-Nogo-A 162 
antibody treatment (n= 11). A pre-hoc power calculation (power = 80% and alpha = 163 
0.05) indicated a minimal group size of n= 10 rats. The pump implantation procedure 164 
was performed as previously described(Ineichen et al., 2017). Briefly, immediately 165 
following the spinal cord injury, a second laminectomy at vertebrate level L2 was 166 
performed and a fine intrathecal catheter (32 Gauge, ReCathCo) was inserted into 167 
the subarachnoid space and pushed in cranial direction towards the lesion for 1 cm. 168 
The catheter was connected to an osmotic minipump (Alzet 2ML2) which 169 
continuously delivered over 14 days either an anti-Nogo-A antibody (mAB 170 
11C7)(Oertle et al., 2003) or an inactive control antibody (Anti-BrdU, Serotec) into the 171 
intrathecal space (5 μl/h, 3 mg antibody/ml). In this way, 6 mg antibodies were 172 
applied in total over 14 days. Pump and catheter were removed 15-16 days post 173 
implantation under 5% Isoflurane (Piramal Healthcare) anesthesia and the skin was 174 
closed by sutures. 175 
Urodynamic and external urethral sphincter EMG measurements: Procedures 176 
were performed as previously described(Schneider et al., 2015; Foditsch et al., 177 
2018). Acclimatization of the rats to the urodynamic setup was performed before 178 
catheter and electrode implantation. Awake rats were positioned in a modified 179 
restrainer (modified from item # HLD-RM, Kent Scientific, Connecticut, USA) with a 180 
  
 10 
hole situated under the orifice of the urethra. The restrainer was then placed in a 181 
modified Small Animal Cystometry Lab Station (Catamount Research and 182 
Development Inc.; St. Albans, Vermont, USA) with a scale below the funnel. The 183 
bladder catheter was attached to a syringe pump with an in-line pressure transducer 184 
and the electrodes were connected to an amplifier/converter. Saline was instilled 185 
(120 μL/min) and all parameters (pressure, scale, voltage) recorded simultaneously 186 
for at least 3 voiding cycles. Urodynamic measurements were performed during the 187 
light phase. For data assessment, the maximum voiding detrusor pressure was 188 
measured as the peak of the intravesical pressure during voiding (Figure 2 a). Voided 189 
volume was measured as the change in weight on the scale (assuming a density 190 
approaching 1). To serve as a measurement of the rigidity of the bladder wall, 191 
bladder compliance was calculated as the intravesical pressure increase (threshold 192 
detrusor pressure minus baseline detrusor pressure) divided by the voided volume. 193 
Urodynamic and behavioral assessments were performed on randomly number 194 
coded animals in a fully blinded fashion. Measurements were analyzed blinded using 195 
an adapted LabVIEW program.  196 
EMG analysis: The external urethral sphincter (EUS)-EMG was bandpass filtered (2 197 
Hz to 2 kHz). The frequency spectrogram was analyzed with a self-programmed 198 
application based on LabVIEW version 2012 (National Instruments, Austin, Texas, 199 
USA). The 45-second-long EMG signal is sliced into 4096 samples, a typical 200 
graphical representation of a spectral heatplot, of whom 3596 are overlapping (shift is 201 
500 samples). After taking a hanning window of the signal, a fast Fourier 202 
transformation was generated. As a result, we obtained a power value for each 203 
frequency at every computed time point. Before graphic processing, the signal was 204 
up scaled by a multiplication factor to assure that the signal consists, after 205 
logarithmizing, mainly of positive values. The logarithmized signal was also scaled up 206 
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by factor 20. This signal was then plotted as color map with Jet Colormap. All 207 
frequencies above 500 Hz were neglected.  208 
Quantification of high-frequency EUS-EMG activity was achieved by summing every 209 
high-frequency power value in the period of interest (before micturition = “r”, during 210 
micturition = “s”, or after micturition = “t”; Figure 1 j-k) and dividing it by the sum of 211 
every high-frequency power value in the whole period analyzed (labelled as “u”; 212 
Figure 1 j-k). Data are shown in percentage. 213 
Perfusion fixation and tissue preparation: Rats were euthanized with an i.p. 214 
overdose of Pentobarbital (300mg/mL, Streuli Pharma AG). Animals were 215 
transcardially perfused first with 150 mL Ringer solution (B.Brown Medical) 216 
containing 1% Heparin (B. Brown Medical), followed by 300 mL of 4% 217 
Paraformaldehyde solution (Paraformaldehyde, PFA, Sigma-Aldrich) containing 5% 218 
sucrose and phosphate-buffered at pH 7.4. Spinal cords were dissected and post-219 
fixed for 24 hrs at 4 °C in a solution containing 4 % paraformaldehyde and 15 % 220 
saturated picric acid for immunohistochemistry, or 4 % paraformaldehyde (Sigma-221 
Aldrich Chemie GmbH, Buchs, Switzerland) in 0.1 M phosphate buffer pH 7.4 for 222 
RNAScope in-situ hybridization. Afterwards, spinal cords were transferred to 30% 223 
sucrose in 0.1 M phosphate buffer, pH 7.2 and stored for three days for cryo-224 
protection. The tissue was embedded in Tissue-Tek OCT compound, frozen in 2-225 
Methylbutane (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) cooled to -40 °C 226 
with liquid nitrogen and stored at -20 °C until further processing. For 227 
immunohistological analysis, 40-μm-thick L6-S1 spinal cord cross-sections were cut 228 
on a cryostat and collected on slides (Superfrost plus, Huberlab, Aesch, Switzerland), 229 
and kept at -20 °C until further processing. For in-situ hybridization analysis, 10-μm-230 
thick L6-S1 spinal cord cross sections were collected free-floating in 4 °C cold 0.1 M 231 
phosphate buffer and kept in anti-freeze solution (15 % sucrose, 30 % ethylene 232 
  
 12 
glycol in 50 mM phosphate buffer) at -20 °C until further processing. For histological 233 
lesion site analysis, T7 – T10 spinal cord sections were mounted on slides, dried on a 234 
heating plate at 60 °C for 10 min and then stored at -20 °C until further processing. 235 
Assessment of lesion completeness: Coronal 40-μm cryostat serial sections of the 236 
injury site were manually reconstructed based on Nissl staining (Cresyl violet) in 237 
Photoshop software (Adobe, San José, USA). The percentage of spared white matter 238 
at the largest lesion extent was calculated. Initial comparison of Nissl staining and 239 
neurofilament 160 immunohistochemical staining showed a very high correlation 240 
between the two protocols (Figure 7 a-c). Low values of spared white matter were 241 
arduous to categorize into complete or incomplete groups based on the images. This, 242 
together with the fact that animals with a spared white matter below 3 % were equally 243 
distributed between the groups, lead to the conclusion that rats with a spared white 244 
matter below 3 % were considered to have a complete lesion.  245 
  246 
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Immunohistochemistry: On-slide spinal cord cross-sections were thawed for 10 min 247 
and then washed three times with 0.1 M phosphate buffer pH 7.2. Afterwards, they 248 
were permeabilized in TNB (0.5% TopBlock; LuBioScience in 0.1 M Tris) containing 249 
0.2% Triton X-100 for 60 min at room temperature, and subsequently incubated with 250 
the primary antibody (rabbit-anti-CRF 1:400, Salk Institute, California) diluted in TNB 251 
and hypotonic 0.01 M phosphate buffer containing 0.05 % Triton X-100 at 4°C for 24 252 
h. The sections were then washed three times in 0.1 M PBS for 10 min each and 253 
incubated with the secondary antibody (goat-anti-rabbit-Cy3 1:300, Jackson 254 
ImmunoResearch Laboratories). Stained sections were washed three times in 0.1 M 255 
phosphate buffer for 10 min each, finally incubated in 0.05 M Tris, pH 8.0, for 10 min, 256 
air-dried overnight at 4°C, and coverslipped with fluorescence mounting medium 257 
(Mowiol, Merck). Slides were stored at 4 °C upon imaging. 258 
The specificity of the signal was assessed by omitting the incubation-step of the 259 
sections in the primary antibody. 260 
RNAScope in-situ hybridization: Sequences of target probes, preamplifier, 261 
amplifier, and label probes are proprietary and commercially available (Advanced 262 
Cell Diagnosis). Here, we used probes against rat glycine transporter 2 (GlyT2, 263 
Slc6a5), glutamic acid decarboxylase 2 (GAD2), and vesicular glutamate transporter 264 
2 (vGluT2, Slc17a6). 265 
Experimental protocols were according to Advanced Cell Diagnosis. Briefly, slides 266 
were thawed at room temperature for 15 min. Subsequently, slides were treated with 267 
ACD hydrogen peroxide for 10 min and washed twice in water for 2 min each, before 268 
incubation in ACD target retrieval buffer for 10 min at 98-100 °C. Slides were washed 269 
first in water and then in 100 % EtOH (Reuss Chemie, Taegerig, Switzerland), and 270 
then protease treatment was applied for 30 min at 40 °C in the ACD HybEZTM oven. 271 
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Subsequently, sections were incubated in a mix containing the three hybridization 272 
probes for 2 h at 40 °C. After washing the slides twice in ACD washing buffer, the 273 
three probes were amplified in a consecutive manner, with two washing-steps in ACD 274 
washing buffer in-between each amplification-step. Further amplification-steps were 275 
performed with HRP detecting the specific channel of the different probes, always 276 
with washing steps with ACD washing buffer in-between. The signals were developed 277 
with TSA Plus fluorescein, TSA Plus Cyanin3, and TSA Plus Cyanin5 (TSA Cy3, 278 
Cy5, TMR, Fluorescein Evaluation kit, PerkinElmer, USA) for the probe targeting 279 
GlyT2, GAD2, and vGluT2, respectively. After the development of the last probe, 280 
sections were washed twice in ACD washing buffer and counterstained with ACD 281 
DAPI for 45 s at room temperature. Slides were coverslipped using fluorescence 282 
mounting medium (Mowiol, Merck) and let dry overnight in the dark. Afterwards, they 283 
were stored at 4 °C upon imaging. 284 
Quantification of immunofluorescent signal: The CRF signal was quantified by 285 
imaging three randomly chosen sections with a confocal microscope (40x, Olympus 286 
FV1000, Olympus America). Microscope and laser parameters, such as laser 287 
intensity, were optimized during the first imaging and kept constant across all 288 
sections. Mosaic pictures were imaged and processed within Olympus FV1000 289 
software. Maximum intensity projections were created, and pictures were exported in 290 
tiff format for investigation. Further analyses were performed with the Fiji image 291 
processing software (version 1.0, ImageJ, National Institutes of Health). Mean grey 292 
values for the regions of the dorsal horn, intermediolateral nucleus, and dorsal grey 293 
commissure were measured in the three sections and background intensities 294 
obtained from the central canal, where no signal is expected, were subtracted for 295 
each region. The values were normalized to the equivalent values of the intact 296 
animals. 297 
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Quantification of RNAScope in-situ hybridization: Five to seven sections per 298 
animal were imaged with a fluorescent microscope (20x, Zeiss Axio Scan.Z1, Zeiss). 299 
Three randomly chosen pictures were analyzed with Fiji and a custom-made 300 
MATLAB (2017b, The MathWorks Inc., Natick, USA) script. Briefly, the coordinates of 301 
each stained cell were retrieved within Fiji, and then used to plot the cells to a 302 
standardized spinal cord cross section template with MATLAB, thereby normalizing 303 
the analysis to potential tissue distortion. The number of GlyT2-, GAD2-, and vGluT2-304 
positive cells was calculated within the laminae 1, 2, 3, which reflect the dorsal horn, 305 
laminae 4,5, which comprehend the intermediolateral nucleus, and lamina X, 306 
comprising the dorsal grey commissure. 307 
Statistical analysis: Data are reported as mean ± standard deviation (SD). Q-Q-308 
plots were generated of all data and visually assessed, all data are assumed to be 309 
approximately normally distributed. For the comparison of the impact of spinal cord 310 
injury on bladder function by urodynamics, immunohistochemistry, and in-situ 311 
hybridization, data were analyzed with a one-way repeated-measures ANOVA 312 
followed by Bonferroni’s post hoc testing. For comparison of unrelated samples, an 313 
unpaired t-test was used. The value of significance was considered at p<0.05. Pre-314 
hoc power calculations were performed with alpha being 0.05 and a power of 80%. 315 
Statistical analyses were performed using STATA statistical software, version 14 316 
(StataCorp, College Station, Texas, USA).  317 
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Results 318 
Lower urinary tract dysfunction following spinal cord injury in adult rats 319 
Animals were injured at day 0 and lower urinary tract function was assessed once a 320 
week for 4 weeks (Figure 1 a). On day 3-5 after the lesion, all rats in the SCI groups 321 
(complete and incomplete lesions) showed a complete initial paralysis of both 322 
hindlimbs as assessed by the BBB score (data not shown)(Basso et al., 1995). The 323 
T8 level bilateral partial transections interrupted between 2 and 55 % of the spinal 324 
cord white matter (Figure 7); spared white matter was mostly found in the ventral and 325 
ventro-lateral funiculi, often unilateral only. One week after injury, most rats of the 326 
incomplete lesion groups started to develop hind limb movements resulting into a 327 
BBB score > 10 three weeks post injury. Completely spinal cord injured animals 328 
showed a persisting severe impairment of hind limb function until the end of the 329 
experiment, i.e. up to four weeks post injury. The impairments observed in the rats 330 
are comparable to human SCI patients with American Spinal Injury Association 331 
(ASIA) impairment scale (AIS) A for the complete spinal cord injury group and AIS C 332 
for the incomplete SCI group (www.ais.emsci.org). 333 
In all groups, bladder function was completely absent during the first week after injury 334 
and, very much in contrast to locomotor performance, showed only very limited 335 
spontaneous recovery.  In both SCI groups, maximum detrusor pressure at 7 days 336 
post injury dropped significantly (p< 0.05) to about half of its value before SCI (Figure 337 
1 b). Over the following 3 weeks, maximum detrusor pressure constantly increased, 338 
exceeding the baseline measurements at 4 weeks post injury. However, maximum 339 
detrusor pressure also increased in the intact group, reaching a value of 164 % of the 340 
baseline, a phenomenon that may be related to the chronic implantation of a bladder 341 
catheter. During voiding, maximum flow rates dropped to half of the pre-injury values 342 
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in both SCI groups (Figure 1 c). Bladder compliance was reduced in both SCI groups 343 
at 4 weeks post injury (Figure 1 d). Voiding time increased from 2 weeks post injury 344 
on (Figure 1 e). Voided volume was strongly and significantly reduced after injury, 345 
showing a certain degree of recovery but remaining significantly below baseline 346 
values in both injury groups until the end of the experiment (Figure 1 f). The intact 347 
group showed an increase of the voided volume over time compared to pre-lesion 348 
baseline. All these urodynamic findings are highly coherent to urodynamic 349 
observations made in human SCI patients and mirror the human acute and early 350 
chronic stages after spinal cord injury(Groen et al., 2016). 351 
SCI induced changes in external urethral sphincter EMG activity: In intact rats, the 352 
EMG of the external urethral sphincter showed strong peak activity in the high 353 
frequency range (21-500Hz, representing mainly striated muscle activity (Solomonow 354 
et al., 1990)) at the high filling state immediately preceding voiding, as well as after 355 
voiding. High frequency activity was low during voiding (Figure 1 j and Figure 2 a, d), 356 
whereas in contrast, slow wave bursting activity (2-20Hz, representing mainly smooth 357 
muscle activity (Domino et al., 2017)) was prominent (Figure 1 j and Figure 2 a, d). 358 
One week after injury, all spinal cord injured rats suffered from urinary retention and 359 
were unable to void by themselves. Urodynamic assessments confirmed this 360 
observation showing an acontractile bladder in all rats, which led to overflow 361 
incontinence once the bladder reached its maximum capacity (Figure 2 b, e). 362 
Sixteen out of 17 rats with either complete or incomplete SCI developed DSD, 363 
starting 1-2 weeks after the lesion, characterized by tonic high frequency sphincter 364 
EMG activity (21-500Hz) during the voiding phase. This resulted in interrupted urine 365 
release and highly prolonged voiding phases (Figure 1 k and Figure 2 c, f). These 366 
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characteristic features again closely resemble the situation seen in severely spinal 367 
cord injured human patients. 368 
Urodynamic and external urethral sphincter parameters were not influenced by lesion 369 
completeness: No significant differences were found in any urodynamic parameter 370 
when the large, incomplete lesions and complete spinal cord injured animals were 371 
compared (Figure 1 b-f). Also, we did not find differences in high frequency activity of 372 
the external urethral sphincter EMG during voiding (Figure 1 h-i) between incomplete 373 
and complete SCI groups. 374 
Effects of anti-Nogo-A antibody treatment on neurogenic lower urinary tract 375 
dysfunction after incomplete spinal cord injury 376 
Anti-Nogo-A antibody therapy significantly reduced important urodynamic 377 
abnormalities in incompletely spinal cord injured animals when compared to 378 
incompletely lesioned animals treated with control antibody (Figure 3 a): Four weeks 379 
after SCI, we observed significant changes towards more physiological values in 380 
maximum detrusor pressure (Figure 3 b, p= 0.01), maximum flow rate (Figure 3 c, p= 381 
0.05), compliance (Figure 3 d, p= 0.006), and voided volume (Figure 3 f, p= 0.002) of 382 
anti-Nogo-A treated SCI animals. Voiding time four weeks after injury did not differ 383 
between the treated and control group (Figure 3 e, p > 0.05). Anti-Nogo-A antibodies 384 
also significantly reduced external urethral sphincter activity during voiding in 385 
incompletely spinal cord injured animals compared to incompletely lesioned animals 386 
treated with control antibody: Four weeks after SCI, we found a significant reduction 387 
in the proportion of high frequency EMG values during voiding (p= 0.002) in the anti-388 
Nogo-A antibody treated animals when compared to control antibody treated spinal 389 
cord injured animals (Figure 3 g). 390 
  391 
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Anti-Nogo-A treatment effects on neurogenic lower urinary tract dysfunction 392 
after complete versus incomplete spinal cord injury 393 
We further investigated if the observed effect of anti-Nogo-A antibody therapy in 394 
incompletely spinal cord injured rats could be replicated in animals with a complete 395 
SCI (Figure 4 a). Anti-Nogo-A antibody treated animals showed again a trend 396 
towards a more pronounced treatment effect in incompletely spinal cord injured 397 
animals compared to incompletely lesions animals treated with control. Several of the 398 
urodynamic abnormalities were reduced starting 2-3 weeks after SCI (Figure 4 b-g). 399 
Four weeks after SCI, the anti-Nogo-A antibody treated group showed a reduction in 400 
maximum detrusor pressure (50%, Figure 4 b), maximum flow rate (32%, Figure 4 c), 401 
compliance (46%, Figure 4 d), voiding time (62 %, Figure 4 e), and voided volume 402 
(34%, Figure 4 f) when compared to the control antibody treated group. The 403 
proportion of high frequency EMGs during voiding showed the biggest change; it was 404 
decreased by 73% in the anti-Nogo-A treated animals (Figure 4 g). Very much in 405 
contrast to these group-differences in the incompletely lesioned rats, no effect of anti-406 
Nogo-A therapy on lower urinary tract function was observed in animals with a 407 
complete SCI (Figure 4 b-g). However, no statistical testing was performed in this 408 
experiment due to the restricted number of animals per group. 409 
  410 
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Neuroanatomical changes in the lumbo-sacral spinal cord after injury and 411 
anti-Nogo-A antibody treatment 412 
The neuropeptide CRF is highly enriched in PMC neurons projecting to the lumbo-413 
sacral spinal cord(Valentino et al., 1994; Verstegen et al., 2017). Immunofluorescent 414 
stainings for CRF in cross sections of the L6-S1 spinal cord revealed three main 415 
target regions innervated by CRF-positive fibers: lamina II of the dorsal horn (Lam II), 416 
the intermediolateral nucleus (IML), and Lamina X of the ventral grey matter (Lam X) 417 
(Figure 5 a). Interestingly, the IML contains the preganglionic autonomic 418 
motoneurons responsible for bladder contraction(De Groat and Ryall, 1968; 419 
Nadelhaft and Booth, 1984), while the Lam X contains interneurons that were shown 420 
to modulate the activity of somatic motoneurons innervating the bladder and external 421 
urethral sphincter(Marson, 1997; Nadelhaft and Vera, 2001). The observed CRF 422 
signal in Lam II is believed to originate from innervating peripheral sensory 423 
fibers(Skofitsch et al., 1985; Kim et al., 2011), since previous anterograde tracings 424 
from the PMC did not result in labelling of this region(Verstegen et al., 2017). Four 425 
weeks after incomplete SCI, animals treated with control antibodies showed a strong, 426 
significant decrease in CRF-positive innervation of Lam X compared to non-injured 427 
animals (p=0.004). In contrast, the density of CRF-positive fibers and terminals in this 428 
region in the injured anti-Nogo-A antibody treated rats was not different from that of 429 
intact rats (p=0.99) but was significantly higher than that of the control antibody spinal 430 
cord injured animals (Figure 5 b-d/ k; p=0.009). In the IML region, both injury groups 431 
showed a reduced CRF-positive fiber density compared to intact animals (Figure 5 e-432 
g, m; p=0.0001 and 0.0006, respectively). Anti-Nogo-A treated rats showed a trend 433 
for higher values (Fig. 5). In contrast, no difference was observed between the two 434 
injury groups (p= 0.33) in the Lam II CRF-innervation, which significantly decreased 435 
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in both spinal cord injured groups when compared to intact rats (Figure 5 h-j/ l; 436 
p=0.02). 437 
We further analyzed the numbers of glycinergic, GABAergic, and glutamatergic 438 
interneurons located in the segments L6-S1 of the spinal cord using in-situ 439 
hybridization for the respective cell type specific markers GLYT2, GAD2 and 440 
VGLUT2 mRNAs. No differences in the number of glycinergic cells expressing 441 
GLYT2 mRNA were observed between intact animals and rats with large but 442 
incomplete SCIs treated with either control or anti-Nogo-A antibodies in none of the 443 
regions analyzed, i.e. Laminae I-III, IV-V, and X (Figure 6 a, e, f). The number of 444 
GABAergic, GAD2 mRNA-positive cells showed a trend towards a decrease in cell 445 
number in all areas analyzed. However, only the dorsal grey commissure area 446 
showed a small but significant reduction in GAD2-positive neurons in the spinal cord 447 
injured, control antibody treated rats when compared to intact animals (p= 0.04). 448 
Interestingly, this reduction in cell-number was not present in the anti-Nogo-A treated 449 
SCI group (Figure 6 b/g). Furthermore, we did not observe any difference between 450 
groups in the number of glutamatergic, VGLUT2-positive neurons in neither laminae 451 
I-III, IV-V, nor X (Figure 6 c, e, i). 452 
  453 
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Discussion 454 
A massive increase in EMG activity of the external urethral sphincter during the 455 
voiding phase was the most prominent change observed using urodynamic 456 
measurements in adult rats with either an incomplete or complete lesion in the low 457 
thoracic spinal cord. This wrongly timed increase in EUS-EMG activity is a hallmark 458 
for DSD, which is defined by a dys-synergistic contraction of the external urethral 459 
sphincter during voiding resulting in increased bladder pressure and therefore 460 
compromised voiding. In humans, this often results in urinary reflux to the kidneys 461 
and over time to life-threatening kidney damage(Panicker et al., 2015). Interestingly, 462 
like in patients with spinal cord injury, the characteristic DSD features in rats 463 
developed over time, i.e. at 2-4 weeks after injury, which is very much in line with the 464 
human condition (1-6 months in humans(Bywater et al., 2018)). Our findings in rats 465 
are therefore highly translational and comparable to data from human SCI 466 
patients(Weld et al., 2000; Fowler et al., 2008; Schops et al., 2015). Intrathecal 467 
administration of anti-Nogo-A antibodies for 2 weeks after a large but incomplete T8 468 
SCI resulted in a reduction of the impairment of several key urodynamic functions at 469 
4 weeks post lesion: among others, the EMG overactivity of the external urethral 470 
sphincter during voiding recovered nearly back to pre-lesion baseline levels. This was 471 
in great contrast to control antibody treated SCI animals. However, no treatment 472 
effect was observed in animals with a complete spinal cord injury treated with anti-473 
Nogo-A antibody. These findings indicate a crucial role of the remaining descending 474 
ventral tract fibers (4-38% of white matter sparring in our study) in the anti-Nogo-A 475 
treatment enhanced restoration of bladder function. 476 
In human spinal cord injured patients, the development of neurogenic lower urinary 477 
tract dysfunction after spinal cord injury follows a typical time course, which is 478 
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characterized by an initial phase of detrusor and sphincter muscle inactivity (flaccid 479 
bladder), resulting in incontinence and high post void residuals(Panicker et al., 2015). 480 
A very similar situation was encountered in our rats in all the experimental SCI 481 
groups at 7 days post injury. Absence of descending control and spinal shock are the 482 
most likely reasons for this condition. Detrusor overactivity and simultaneous 483 
abnormal contractions of the external urethral sphincter during voiding(Abrams et al., 484 
2002) then lead to increased intravesical pressure. In our animal model, the 485 
incomplete thoracic SCI resulted in the development of characteristic DSD features 486 
within the first 4 weeks following injury. Impairment of most of the urodynamic and 487 
EUS-EMG parameters was much more pronounced after an incomplete lesion than 488 
after a complete SCI. This finding points to an important role of spared descending 489 
fibers and their potential detrimental, spontaneous plastic changes after partial injury 490 
for the initial development of DSD.  491 
Intrathecal delivery of function blocking anti-Nogo-A antibodies, which have been 492 
shown to promote nerve fiber sprouting and regeneration in the adult mammalian 493 
CNS(Liebscher et al., 2005; Lindau et al., 2014), for the first two weeks after the 494 
lesion had a strong positive effect on the recovery of bladder function. Several of the 495 
key urodynamic and electrophysiological parameters showed significant and 496 
pronounced improvement in the anti-Nogo-A compared to the control antibody 497 
treated SCI group. Most strikingly, the anti-Nogo-A antibody treatment led to a 498 
pronounced recovery of the physiological external urethral sphincter function during 499 
voiding. Anti-Nogo-A antibody treatment has been shown to induce regeneration and 500 
sprouting of the corticospinal tract(Liebscher et al., 2005; Freund et al., 2006) and 501 
restoration of the serotonergic projection density(Mullner et al., 2008) after large but 502 
incomplete SCI in several species, including macaque monkeys. 503 
Immunohistochemical staining against the neuropeptide CRF allowed us to 504 
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specifically visualize descending projections from the PMC to the lumbosacral spinal 505 
cord(Skofitsch et al., 1985; Kim et al., 2011). In line with existing literature, animals 506 
with a SCI showed a massive decrease in CRF-positive fibers in the lumbosacral 507 
spinal grey matter at 4 weeks after injury(Studeny and Vizzard, 2005). Interestingly, 508 
animals that were treated with the anti-Nogo-A antibodies during the first two weeks 509 
after injury showed CRF fiber densities comparable to intact rats in Lam X, but not in 510 
Lam II or in the IML, where the PMC fiber loss was comparable to the control 511 
antibody treated SCI rats. This suggests that, in the anti-Nogo-A treated animals, the 512 
spared descending fibers from the PMC sprouted below the level of the injury in a 513 
specific target region, Lam X, thereby restoring functional, supraspinal input from the 514 
key bladder control system located in the brainstem. Keller and colleagues recently 515 
showed that in addition to the CRF-positive neurons, the PMC contains an additional 516 
population of neurons that is positive for the estrogen receptor 1 alpha. This estrogen 517 
receptor 1 alpha-positve nueornal population in the PMC is crucial for the correct 518 
function of the external urethral sphincter and thereby for voluntary control of 519 
micturition(Keller et al., 2018). Thus, CRF positive fibers might not be the only key 520 
players in the observed recovery of lower urinary tract function following anti-Nogo-A 521 
therapy. In fact, a number of additional changes in the circuitry underlying the control 522 
of bladder function will be enhanced by the temporary neutralization of the neurite 523 
growth inhibitory factor Nogo-A and thereby might contribute to the reconfiguration of 524 
the bladder control on spinal and supraspinal levels(Bareyre et al., 2004; Filli et al., 525 
2014). Our results are also in line with an earlier study which found that rats with 526 
slightly smaller incomplete lesions recovered functional bladder control earlier if 527 
treated with anti-Nogo-A antibodies(Liebscher et al., 2005). 528 
Former studies investigating the neural circuits involved in lower urinary tract function 529 
showed that the PMC projects to GABAergic and glycinergic interneurons in the 530 
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lumbosacral cord(Blok and Holstege, 2000; Sie et al., 2001), and that a SCI causes a 531 
downregulation of glycine and GABA in the spinal cord and lumbosacral dorsal root 532 
ganglia of rats(Miyazato et al., 2003; Miyazato et al., 2008a). Furthermore, spinal 533 
cord injured animals affected by detrusor overactivity and DSD showed some 534 
degrees of recovery after dietary supplementation of glycine, or intrathecal 535 
application of GABAA or GABAB agonists(Miyazato et al., 2005; Miyazato et al., 536 
2008b). These results indicate that inhibitory intraspinal connectivity is essential to 537 
coordinate bladder and sphincter function. Our results also suggest that these 538 
interneuron populations in the lumbosacral cord tend to decrease in number after 539 
injury, possibly due to a lack of descending inputs and therefore proper synaptic 540 
innervation. The decrease in numbers of GABAergic interneurons was dampened in 541 
the animals treated with anti-Nogo-A antibodies. This can most likely be explained by 542 
anti-Nogo-A treatment enhancing the sprouting of spared descending fibers below 543 
the injury site, thereby restoring critical synaptic inputs to the interneurons. 544 
A human phase I safety and tolerability trial with intrathecal application of anti-Nogo-545 
A antibodies in acutely spinal cord injured patients was concluded 546 
successfully(Kucher et al., 2018). Phase two randomized controlled European 547 
multicenter trial testing for upper limb motor recovery in acute tetraplegic patients is 548 
currently on-going (https://nisci-2020.eu). Bladder parameters will be monitored as 549 
part of the panel of secondary read-outs in this trial. Data addressing potential 550 
beneficial effects of Nogo-A suppression after SCI in humans should therefore 551 
become available soon. 552 
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Figure legends  723 
 724 
Figure 1: Time-course of lower urinary tract dysfunction after SCI. – a. Study design. b-f. 725 
Urodynamic parameters change after spinal cord injury. b. Maximum detrusor pressure 726 
[cmH2O]; c. Maximum flow rate [mL/s]; d. Bladder compliance [mL/cmH2O]; e. Voiding time 727 
[s]; f. Voided volume [mL]. g-k. External urethral sphincter EMG analysis before and 1, 2, 3, 728 
and 4 weeks after incomplete or complete spinal cord injury. g. EMG power spectrum shows 729 
highest percentual power for the high frequencies (21-500 Hz) before voiding in intact rats. 730 
h. After a large but incomplete spinal cord injury, the high frequency power activity (21-731 
500Hz) of the external urethral sphincter shifts to the micturition phase starting at d.7, a 732 
condition typical for DSD. i. Similar but less pronounced shift in complete SCI rats. j. EUS-733 
EMG Spectrogram of one voiding cycle of an intact rat showing increased high frequency 734 
power activity (21-500 Hz, bigger quadrant) before micturition, followed by slow wave 735 
bursting activity (1-20 Hz, smaller quadrant) during micturition. k. EUS-EMG spectrogram of 736 
one voiding cycle of an incompletely spinal cord injured rat four weeks after spinal cord 737 
injury. Percentual power in g-i was calculated dividing the power of high-frequencies in the 738 
period of interest (before = r; during = s; after = t) by the whole analyzed period (u). 739 
Statistical testing: data of intact and both complete and incomplete spinal cord injury were 740 
analyzed with a one-way repeated-measures ANOVA followed by Bonferroni’s post hoc 741 
testing; *= p<0.05; **= p<0.01 and ***= p<0.001. 742 
 743 
Figure 2: Bladder pressure, voided urine and external urethral sphincter EMGs before 744 
(intact) and 7 and 28 days after incomplete spinal cord injury. DSD is fully developed at 4 745 
weeks after injury. - a., d.: 40 min. (2200 sec.) and 1min. (60 sec.) windows of a 746 
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representative urodynamic tracing from an intact rat with bladder catheter and external 747 
urethral sphincter EMG showing filling/voiding cycles. Top panels: bladder pressure, middle 748 
panels: urine secreted (weight), bottom panels: external urethral sphincter EMG. Lowest 749 
panel: Heat plot of EMG frequency spectrogram where red represents a high power of the 750 
corresponding frequency at the current time point and blue represents low power.  b., e. 751 
Spinal cord injured rat at one week after injury shows a flaccid bladder with continuous flow 752 
of urine and absent sphincter activity c., f. Typical characteristics of DSD at 4 weeks after 753 
injury. During the filling phase there are non-voiding contractions with increasing magnitude 754 
as well as an increase in EUS-EMG activity during voiding.  755 
 756 
Figure 3: Anti-Nogo-A effects on lower urinary tract function in incomplete spinal cord 757 
injury assessed by urodynamics. -  a. Study design; b. Maximum detrusor pressure [cmH2O]; 758 
c. Maximum flow rate [mL/s]; d. Bladder compliance [mL/cmH2O]; e. Voiding time [s]; f. 759 
Voided volume [mL]; g. EMG activity during voiding (period s, Figure 1 j-k) in comparison to 760 
the whole period analyzed (period u, Figure 1 j-k) [%]. Statistical testing: data of anti-Nogo-A 761 
antibody treated rats and control antibody treated rats were analyzed with an unpaired 762 
students t-test; *= p<0.05; **= p<0.01 and ***= p<0.001. Red dashed line reflects the values 763 
of intact animals. 764 
 765 
Figure 4: Anti-Nogo-A effects on lower urinary tract function in incomplete versus 766 
complete spinal cord injury assessed by urodynamics. - a. Study design; b. Maximum 767 
detrusor pressure [cmH2O]; c. Maximum flow rate [mL/s]; d. Bladder compliance 768 
[mL/cmH2O]; e.  Voiding time [s]; f. Voided volume [mL]; g. EMG activity during voiding 769 
(period s, Figure 1 j-k) in comparison to the whole period analyzed (period u, Figure 1 j-k) 770 
[%]; No statistical testing was performed on this study. 771 
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 772 
Figure 5: Innervation of lumbosacral spinal cord by CRF-positive fibers including bulbo-773 
spinal fibers from the pontine micturition center at 28 days after injury. - a. In intact rats 774 
immunofluorescent CRF-positive fibers and terminals are concentrated in dorsal horn lamina 775 
II (Lam II), the intermediolateral column (IML), and Lamina X (Lam X). b-j. High magnification 776 
(40x) of b-d. Lamina X, e-g. Intermediolateral column, and h-j. dorsal horn in intact, spinal 777 
cord injured control antibody treated (Ctr Ab) and injured anti-Nogo-A antibody treated rats. 778 
k-m. Relative optical density quantitation for CRF in Lam X, IML, and Lam II. Data are 779 
presented as means ? SD. Scale bar is 100 ?m in a. and 20 ?m in b-j.; ns = not significant; *= 780 
p<0.05; **= p<0.01; and ***= p<0.001.  781 
 782 
Figure 6: Glutamatergic, GABAergic, and glycinergic neurons in the sacral cord of intact and 783 
spinal cord injured, antibody treated rats at 28 days after injury. a-e. Representative 784 
images of fluorescent in-situ hybridization for mRNA of a. glycine transporter 2 (GlyT2), b. 785 
glutamic acid decarboxylase 2 (GAD2), and c. vesicular glutamate transporter 2 (vGlut2). d. 786 
Sections were counterstained with DAPI. e. Representative image of the three merged 787 
probes, indicating the three analyzed regions Laminae I-III, IV-V, and X. f-h. quantification of 788 
f. glycinergic, g. GABAergic, and h. glutamatergic neurons in the sacral cord of intact animals, 789 
incomplete spinal cord injured animals treated with control antibody (Ctr Ab), and 790 
incomplete spinal cord injured animals treated with anti-Nogo-A antibodies (anti-Nogo-A). 791 
Data are presented as means ? SD. Scale bar is 20 ?m in a-d., and 300 ?m in e.; ns = not 792 
significant; *= p<0.05 793 
 794 
Figure 7: Spinal cord lesion assessment and distribution among groups: a. Schematic 795 
reconstruction of a spinal cord lesion. b. Representative Nissl staining of a spinal cord used 796 
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to reconstruct the lesion size. c. Neurofilament-160 immunohistological staining shows a 797 
high degree of correlation with the Nissl staining. d. Distribution of lesion sizes across the 798 
different animals. e. Comparison of the spared white matter between animals with a spinal 799 
cord injury group and no treatment (SCI only), spinal cord injured rats treated with control 800 
antibody (Ctr Ab), and spinal cord injured animals treated with anti-Nogo-A antibody (anti-801 
Nogo-A) in case of a complete (black) or incomplete (gray) lesion. Data in e. are shown as 802 
median and 10-90 percentile.  803 
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